AOC-1020
AOC-1020First antibody-RNA conjugate (AOC platform) to reach Phase 3. FSHD has no approved disease-modifying therapy.
Emerging drug — Phase 3 readout — POSITIVE
✓ Won · Read out 2025-06Phase 1/2 FORTITUDE positive: del-brax 2 mg/kg achieved >50% reduction in DUX4-regulated genes at 4 months, trends of functional improvement. FDA confirmed accelerated approval pathway is OPEN for FSHD. Phase 3 FORWARD initiated as confirmatory study (200 patients, 18 months). FORTITUDE biomarker cohort topline expected Q2 2026.
Regulatory: Accelerated-approval BLA submission planned H2 2026.
→ Source PRNext remaining catalyst
Fresh est.A positive readout makes DUX4 a validated target for the first time. Hover the badge above for what the confidence level means.
What does it do?
DUX4 — Double homeobox 4
Modality: antibody-RNA conjugate (anti-TfR1 mAb conjugated to siRNA)
Program: FORWARD
The 1 Phase 3 trial
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT07038200 | Facioscapulohumeral Muscular Dystrophy; FSHD | 200 | RECRUITING | 2025-06-10 | 2028-05 | Fresh est. |
What's the case for and against?
✓ What's working in its favor
- Phase 1/2 FORTITUDE: significant reduction in DUX4-target gene expression
- Positive functional measure improvements (RWS, MFM-32) in P2
Who else is racing? — 2 other assets at DUX4
| Asset | Sponsor | Status |
|---|---|---|
| Losmapimod | Fulcrum Therapeutics | P3 ReDUX4 missed primary endpoint Sep 2023; relaunched salvage P3 in 2024 |
| Del-zota / EXG002 | Dyne Therapeutics | P1/2 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.